← Back

Policy Updates

Health Ministry Proposes Bringing Antimicrobials Under Central Oversight Through Draft Rules Amendment

Courtlens · AI-generated ·

The Union Health Ministry has proposed amending the New Drugs and Clinical Trials Rules, 2019, to include antimicrobials within the definition of “New Drug”. If finalised, manufacturers would need Central Licensing Authority permission before seeking a manufacturing licence from a State Licensing Authority. The draft is open to objections and suggestions.

Draft amendment would change the regulatory classification of antimicrobials

The Union Ministry of Health and Family Welfare has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019. The proposal, set out in draft Gazette Notification G.S.R. 983 (E) dated 6 November, would add antimicrobials to the definition of “New Drug” under Rule 2(1)(w)(v).

This remains a proposal rather than a final amendment. The draft notification has been issued to obtain public and stakeholder feedback before the Central Government considers whether to finalise it.

Proposed licensing pathway would involve the Central Licensing Authority

If the proposal is finalised as described, manufacturers of products covered by the amended definition would first need permission from the Central Licensing Authority. They would then apply for a manufacturing licence from the relevant State Licensing Authority.

The stated regulatory objective is to bring antimicrobials within the framework that applies to new drugs, thereby adding central scrutiny before the state-level manufacturing-licence application described in the draft.

Ministry links the proposal to product quality and antimicrobial resistance concerns

The Ministry says the proposal responds to concerns that manufacturing licences for antimicrobial products may be granted without adequate regulatory scrutiny. The concerns specifically include the absence of studies such as bioavailability or bioequivalence and stability studies.

According to the source, the absence of these assessments may affect product quality, safety and efficacy. It also states that substandard or ineffective antimicrobials can contribute to the development and spread of antimicrobial resistance and create patient-safety risks.

Public can submit objections and suggestions on the draft

Objections and suggestions may be submitted to the Under Secretary (Drugs), Ministry of Health and Family Welfare, at the address specified in the draft, or by email. The stated deadline is 30 days from the date on which copies of the Gazette containing the draft rules are made available to the public.